अApnaFunda
Menu

TORRENT PHARMACEUTICALS LTD (TORNTPHARM)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.49 / 100
Profitability 75Growth 69Balance sheet 4
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.56 / 100
Price 59Earnings 39FII/DII 71
Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESLAURUS LABS

Share price

Closing priceAdjusted for splits and bonus issues.

₹4,780 latest close · +0.2% over the last 90 sessions

₹4,600₹4,800₹5,000Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹4,600₹4,800₹5,000Jul 3Sep 4Nov 9

₹4,780 month-end · +28.5% over 12 months

₹4,000₹4,500₹5,000Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹4,000₹4,500₹5,000Nov '25May '26Nov '26

₹4,780 month-end · +124.8% over 3 years

₹2,000₹3,000₹4,000₹5,000Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹2,000₹3,000₹4,000₹5,000Nov '23May '25Nov '26

₹4,780 month-end · +425.6% since Jan '19

₹2,000₹4,000Jan '19Aug '20Mar '22Sep '23Apr '25Nov '26 ₹2,000₹4,000Jan '19Dec '22Nov '26

52-week range ₹3532.60 to ₹5250.00 · 1-year volatility 22.3%

Was the rally earned?

+29%share price, 1 yearMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 62.9x to 75.0x); per-share earnings added 8 points.
  • The share count rose 3%.
Net profit growth: +12 pts. Points of the price return explained by net profit growing (or shrinking).+12 ptsNet profit growthP/E change: +20 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+20 ptsP/E changeShare count change: −3 pts. Points of the price return explained by the share count changing. More shares count against the price.−3 ptsShare count changeShare price: +29%+29%Share priceNet profit growth: +12 pts. Points of the price return explained by net profit growing (or shrinking).+12ProfitP/E change: +20 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+20P/EShare count change: −3 pts. Points of the price return explained by the share count changing. More shares count against the price.−3SharesShare price: +29%+29%Share price
Net profit growth+12 ptsNet profit rose about 11%, which lifts the price.
P/E change+20 ptsThe P/E rose from 62.9x to 75.0x, which lifts the price.
Share count change-3 ptsShare count rose 3%, which lowers the price.
+125%share price, 3 yearsEarnings-driven

Mostly yes.

  • Per-share earnings added 85 points to the rise, while the multiple moved less (P/E 57.8x to 75.0x).
  • The share count rose 3%.
Net profit growth: +89 pts. Points of the price return explained by net profit growing (or shrinking).+89 ptsNet profit growthP/E change: +40 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+40 ptsP/E changeShare count change: −4 pts. Points of the price return explained by the share count changing. More shares count against the price.−4 ptsShare count changeShare price: +125%+125%Share priceNet profit growth: +89 pts. Points of the price return explained by net profit growing (or shrinking).+89ProfitP/E change: +40 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+40P/EShare count change: −4 pts. Points of the price return explained by the share count changing. More shares count against the price.−4SharesShare price: +125%+125%Share price
Net profit growth+89 ptsNet profit rose about 78%, which lifts the price.
P/E change+40 ptsThe P/E rose from 57.8x to 75.0x, which lifts the price.
Share count change-4 ptsShare count rose 3%, which lowers the price.
+214%share price, 5 yearsEarnings and multiple

Both mattered.

  • Per-share earnings added 102 points and the multiple added 113 points (P/E 41.1x to 75.0x).
  • The share count rose 3%.
Net profit growth: +107 pts. Points of the price return explained by net profit growing (or shrinking).+107 ptsNet profit growthP/E change: +113 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+113 ptsP/E changeShare count change: −5 pts. Points of the price return explained by the share count changing. More shares count against the price.−5 ptsShare count changeShare price: +214%+214%Share priceNet profit growth: +107 pts. Points of the price return explained by net profit growing (or shrinking).+107ProfitP/E change: +113 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+113P/EShare count change: −5 pts. Points of the price return explained by the share count changing. More shares count against the price.−5SharesShare price: +214%+214%Share price
Net profit growth+107 ptsNet profit rose about 77%, which lifts the price.
P/E change+113 ptsThe P/E rose from 41.1x to 75.0x, which lifts the price.
Share count change-5 ptsShare count rose 3%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-24.7%recovered 2020-01
1-year volatility22.3%annualised
Beta vs sector index0.723-year daily, correlation 0.48
Volume spikes1last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−10%−20%2020202120222023202420252026−23.3% 0%−10%−20%2020202220242026−23.3%
Largest drawdowns

-24.7% (2019-03 peak to 2019-07 low, recovered 2020-01)

-23.6% (2021-12 peak to 2022-05 low, recovered 2022-10)

-21.4% (2020-08 peak to 2021-03 low, recovered 2021-07)

Most recent volume spikes

2026-07-16: 13.7x the 50-day median, price -0.6% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

75.0xP/E todayNear its historic high
Against its own history92nd percentile
CheapestMedian 62.4xDearest

Usual range 40.5x to 74.4x since 2019-01.

Against Health Technology75.0x vs 37.0x
This company
75.0x
Sector median
37.0x

103% above the Health Technology median.

16.7x41.7x66.7x91.6xJan '19Aug '20Mar '22Oct '23May '25Nov '2616.7x41.7x66.7x91.6xJan '19Sep '21May '24Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE54th▼ 33 pts vs a year ago
  • Op. margin96th▲ 4 pts vs a year ago
  • Revenue growth84th▲ 37 pts vs a year ago
  • EPS growth50th▼ 10 pts vs a year ago
  • Debt/equity ↓3rd▼ 27 pts vs a year ago
  • Cash cycle ↓47thflat vs a year ago
  • P/E ↓19thflat vs a year ago
  • 12M momentum66th▼ 22 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~34%annual earnings growth implied by the priceAbove delivered growth

At normalised P/E (five-year average earnings) of 104.7x, a holder earning 12%/yr needs earnings to grow about 33.5%/yr for 10 years, then trade at 15x.

Delivered15.8%/yrEPS, last 10 fiscal years · 3-yr avg to 3-yr avg
Gap+17.7 ptsimplied minus delivered
Rank185thmost demanding of 856

Over time

Implied growth by month (solid) and delivered growth (dashed).

-15%10%35% Jan 2019Nov 2026 -15%10%35% Jan 2019Nov 2026

Change the assumptions

Exit P/E / return11%12%13%
12x34.9%36.2%37.4%
15x32.3%33.5%34.7%
20x29.0%30.2%31.3%

Drag a slider to test other assumptions

Implied: 33.5%/yr

Looking back

  • Jan 2020Price implied 20%/yr; EPS has since grown 26%/yr (7.0 yrs)
  • Jan 2021Price implied 24%/yr; EPS has since grown 13%/yr (6.0 yrs)
  • Jan 2022Price implied 25%/yr; EPS has since grown 12%/yr (5.0 yrs)

Past comparisons cover only companies listed today (survivorship bias) and say nothing about future outcomes.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect. How this is calculated and the market-wide lists.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹4780.00
P/E
75.0x
ROCE
15.0%
Market Cap
₹1.82L cr
Revenue (TTM)
₹15723 cr
P/S
11.6x
P/B
21.7x
ROE
28.9%
Operating Margin
34.0%
Debt / Equity
1.8x
Promoter Holding
68.3%
12M Momentum
28.5%

52-week range

₹3532.60₹5250.00
73% of the way from its 52-week low to its high

Price risk

1Y volatility
22.3%
Beta vs sector
1-year daily
0.77

Balance sheet & cash

Interest cover
operating profit ÷ interest
5.5x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.56x
Share count, 1Y
unchanged

Are profits backed by cash?

6 of 7checks within range1 near a threshold
Other income reliance-6%Within range

Other income as a share of pre-tax profit (trailing twelve months): -6.2%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.56xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.56x (cash from operations ₹8,874 cr, net profit ₹5,705 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow5 of 5 yrsWithin range

Fiscal years with positive free cash flow in the last 5: 5. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+16 daysNear threshold

Debtor days are above the median of the previous three fiscal years by 16 days (79 vs 63). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress2% of fixed assetsWithin range

Capital work-in-progress is 2% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-30 days / 2 yrsWithin range

Days payable changed by -30 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 2 years, promoters trimmed 2.9 pts; DIIs added 2.6 pts; FIIs added 1.4 pts.
  • The number of shareholders rose from 69,117 to 85,776 (+24%) between Dec 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupDec '23Jun '26Change
Promoters71.3%68.3%-2.9 pts
FIIs14.1%15.4%+1.4 pts
DIIs7.1%9.7%+2.6 pts
Public and others7.5%6.4%-1.0 pts

Number of shareholders

85,776shareholders+24% since Dec '23
69k75k80k86k Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Dec '23: 69,117
Mar '24: 71,154
Jun '24: 74,765
Sep '24: 79,848
Dec '24: 85,035
Mar '25: 86,005
Jun '25: 81,856
Sep '25: 78,226
Dec '25: 76,214
Mar '26: 83,811
Jun '26: 85,776
 69k75k80k86k Dec '23Dec '24Dec '25Jun '26
Dec '23: 69,117
Mar '24: 71,154
Jun '24: 74,765
Sep '24: 79,848
Dec '24: 85,035
Mar '25: 86,005
Jun '25: 81,856
Sep '25: 78,226
Dec '25: 76,214
Mar '26: 83,811
Jun '26: 85,776

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−10.2%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like TORRENT PHARMACEUTICALS LTD today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −25% to +7% vs the market, against −6% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −4.7%, 80% range −17.1% to −2.4%), but the matches cluster in only 5 distinct 12-month windows.

Where the 50 outcomes landed

−50%0%+50%+100%
PVRINOX · Feb 2020: −46.5% vs market
WESTLIFE · Aug 2023: −40.5% vs market
BIOCON · Aug 2020: −40.1% vs market
DEVYANI · Aug 2023: −39.0% vs market
UNITDSPR · Mar 2020: −36.1% vs market
METROBRAND · Sep 2025: −35.1% vs market
JKCEMENT · Mar 2021: −32.1% vs market
RELIANCE · Sep 2020: −31.1% vs market
PHOENIXLTD · Feb 2020: −30.2% vs market
LEMONTREE · Oct 2025: −30.1% vs market
JUBLFOOD · Feb 2025: −29.7% vs market
GODREJPROP · Jun 2024: −28.5% vs market
INDHOTEL · Mar 2025: −25.5% vs market
ZYDUSLIFE · Oct 2020: −24.6% vs market
TITAN · Jun 2023: −23.8% vs market
POWERGRID · Mar 2020: −23.8% vs market
BATAINDIA · Jul 2022: −22.8% vs market
JSWINFRA · Mar 2025: −22.6% vs market
FORTIS · Oct 2025: −20.6% vs market
UPL · Feb 2020: −20.6% vs market
MEDANTA · Apr 2024: −18.5% vs market
AARTIIND · Aug 2021: −17.4% vs market
MAXHEALTH · Sep 2025: −17.1% vs market
CHALET · Sep 2025: −11.6% vs market
ADANIPORTS · Mar 2021: −10.8% vs market
RAINBOW · Jun 2025: −9.6% vs market
NH · Jun 2025: −9.3% vs market
MANKIND · Jul 2025: −8.7% vs market
RAMCOCEM · Feb 2020: −7.6% vs market
BHARTIHEXA · Oct 2025: −7.1% vs market
SHREECEM · Mar 2020: −6.6% vs market
BHARATFORG · Sep 2023: −4.3% vs market
NHPC · Oct 2025: −3.2% vs market
KIMS · Aug 2025: −3.1% vs market
ERIS · Feb 2025: −2.7% vs market
ASTERDM · Oct 2025: +6.2% vs market
ULTRACEMCO · Feb 2020: +6.5% vs market
CHOICEIN · Jun 2025: +7.2% vs market
SRF · May 2020: +7.3% vs market
TVSMOTOR · Mar 2024: +8.5% vs market
ANURAS · Sep 2025: +9.6% vs market
BHARTIARTL · Jan 2025: +14.1% vs market
SOLARINDS · Jan 2023: +16.0% vs market
APOLLOHOSP · Oct 2025: +16.2% vs market
SYNGENE · Mar 2020: +25.9% vs market
BLUEDART · Aug 2021: +36.0% vs market
VBL · Jul 2022: +58.9% vs market
NAVINFLUOR · Sep 2025: +77.4% vs market
TRENT · Dec 2023: +98.3% vs market
LAURUSLABS · Sep 2025: +133.9% vs market
Similar setups −10.2%All companies −5.5%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 1 beyond the range shown, drawn at the edge

Similar setups' median
−10.2%
All companies' median
−5.5%
Beat the market
30% vs 44%

50 past situations · 50 companies · 25 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
KIMS
Health Services		 Aug 2025 75x15% +43%−8% −3%
ADANIPORTS
Transportation		 Mar 2021 38x12% +180%−7% −11%
BHARTIHEXA
Communications		 Oct 2025 68x17% +32%−6% −7%
BHARTIARTL
Communications		 Jan 2025 75x13% +39%−8% +14%
TRENT
Retail Trade		 Dec 2023 244x12% +126%0% +98%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
CHALET
Consumer Services		 Sep 2025 73x11% +8%−11% −12%
JUBLFOOD
Consumer Services		 Feb 2025 105x11% +35%−18% −30%
TITAN
Consumer Durables		 Jun 2023 83x25% +57%0% −24%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, P/E and 12-month momentum. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 5 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to TORRENT PHARMACEUTICALS LTD. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

JSW INFRASTRUCTUREJSWINFRA
Industrial Services
70%similar
EPS growthROCE
ADANI PORT AND SPECIAL ECONOADANIPORTS
Transportation
66%similar
market capROCE
BHARTI HEXACOMBHARTIHEXA
Communications
66%similar
promoter holdingmarket cap
JSW ENERGYJSWENERGY
Utilities
65%similar
revenuedebt/equity
NARAYANA HRUDAYALAYANH
Health Services
65%similar
debt/equityROCE
MANKIND PHARMAMANKIND
Health Technology
70%similar
revenuerevenue growth
ZYDUS LIFESCIENCESZYDUSLIFE
Health Technology
51%similar
revenue growthmarket cap
ERIS LIFESCIENCESERIS
Health Technology
48%similar
operating marginEPS growth

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jul '21

  1. NovValuationP/E crossed above the 90th percentile of its own history to date (75.0x).
  2. JulPriceVolume reached 13.7x its 50-day median on 2026-07-16; price -0.6% that day.
  3. JunValuationP/E crossed above the 90th percentile of its own history to date (73.1x).
  4. JunPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
  5. JunDebtDebt / equity rose above 1.0x (1.79x).
  6. MayPriceVolume reached 9.3x its 50-day median on 2026-05-29; price -2.8% that day.
  7. FebPriceVolume reached 8.2x its 50-day median on 2026-02-16; price +4.5% that day.
  8. NovPriceVolume reached 9.8x its 50-day median on 2025-11-10; price +6.6% that day.
Show 22 earlier events
  1. JunPriceVolume reached 7.2x its 50-day median on 2025-06-30; price +2.0% that day.
  2. MarPromoterPromoter holding fell 2.9 pts to 68.3%.
  3. MarInstitutionsFII + DII holding rose 3.0 pts over 2 quarters to 24.4%.
  4. FebPriceVolume reached 9.9x its 50-day median on 2025-02-28; price -1.3% that day.
  5. OctPriceVolume reached 14.4x its 50-day median on 2024-10-30; price -2.4% that day.
  6. JunResultsRevenue (TTM) reached a new high of ₹10,728 cr.
  7. JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
  8. MayPriceVolume reached 5.2x its 50-day median on 2024-05-27; price +1.6% that day.
  9. DecPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
  10. SepPriceVolume reached 9.7x its 50-day median on 2023-09-01; price -3.1% that day.
  11. JunResultsYear-on-year EPS growth turned positive.
  12. JunPeer rankMoved into the top quartile of Health Technology on ROCE (from the 2nd quartile).
  13. MayValuationP/E crossed above the 90th percentile of its own history to date (79.9x).
  14. MayPriceVolume reached 18.1x its 50-day median on 2023-05-31; price +7.1% that day.
  15. SepPriceVolume reached 8.3x its 50-day median on 2022-09-28; price -2.6% that day.
  16. JunResultsYear-on-year EPS growth turned negative.
  17. JunPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
  18. MayPriceVolume reached 16.8x its 50-day median on 2022-05-26; price +10.1% that day.
  19. JanPriceVolume reached 19.8x its 50-day median on 2022-01-27; price -15.1% that day.
  20. NovPriceVolume reached 9.5x its 50-day median on 2021-11-29; price +0.0% that day.
  21. OctValuationP/E fell below the 10th percentile of its own history to date (38.7x).
  22. JulPriceVolume reached 5.5x its 50-day median on 2021-07-28; price +2.7% that day.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history95 months · 2019-01 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1175.0x₹15723 cr28.9%15.0%1.8x
2026-1072.4x₹15723 cr28.1%15.0%1.8x
2026-0975.4x₹15723 cr28.1%15.0%1.8x
2026-0880.2x₹13980 cr27.8%15.0%1.8x
2026-0781.1x₹13980 cr27.8%15.0%1.8x
2026-0673.1x₹13980 cr27.8%15.0%1.8x
2026-0565.7x₹12742 cr32.7%27.0%0.4x
2026-0462.4x₹12742 cr32.7%27.0%0.4x
2026-0362.9x₹12742 cr32.7%27.0%0.4x
2026-0268.5x₹12248 cr30.8%27.0%0.4x
2026-0162.7x₹12248 cr30.8%27.0%0.4x
2025-1260.9x₹12248 cr30.8%27.0%0.4x
2025-1162.9x₹11835 cr28.8%27.0%0.4x
2025-1060.2x₹11835 cr28.8%27.0%0.4x
2025-0960.9x₹11835 cr28.8%27.0%0.4x
2025-0863.1x₹11516 cr27.5%27.0%0.4x
2025-0766.3x₹11516 cr27.5%27.0%0.4x
2025-0660.4x₹11516 cr27.5%27.0%0.4x
2025-0557.7x₹11302 cr29.7%23.0%0.6x
2025-0460.4x₹11302 cr29.7%23.0%0.6x
2025-0358.7x₹11302 cr29.7%23.0%0.6x
2025-0255.4x₹11225 cr28.7%23.0%0.6x
2025-0161.4x₹11225 cr28.7%23.0%0.6x
2024-1263.1x₹11225 cr28.7%23.0%0.6x
2024-1164.8x₹10996 cr27.6%23.0%0.6x
2024-1062.5x₹10996 cr27.6%23.0%0.6x
2024-0966.2x₹10996 cr27.6%23.0%0.6x
2024-0871.2x₹10728 cr26.4%23.0%0.6x
2024-0764.8x₹10728 cr26.4%23.0%0.6x
2024-0657.0x₹10728 cr26.4%23.0%0.6x
2024-0573.3x₹9620 cr21.9%20.0%0.9x
2024-0471.8x₹9620 cr21.9%20.0%0.9x
2024-0370.7x₹9620 cr21.9%20.0%0.9x
2024-0272.5x₹9620 cr21.9%20.0%0.9x
2024-0168.8x₹9620 cr21.9%20.0%0.9x
2023-1262.7x₹9620 cr21.9%20.0%0.9x
2023-1157.8x₹9620 cr21.9%20.0%0.9x
2023-1052.3x₹9620 cr21.9%20.0%0.9x
2023-0952.4x₹9620 cr21.9%20.0%0.9x
2023-0850.1x₹9620 cr21.9%20.0%0.9x
2023-0754.4x₹9620 cr21.9%20.0%0.9x
2023-0651.8x₹9620 cr21.9%20.0%0.9x
2023-0579.9x₹8508 cr14.3%19.0%0.7x
2023-0471.9x₹8508 cr14.3%19.0%0.7x
2023-0366.9x₹8508 cr14.3%19.0%0.7x
2023-0263.6x₹8508 cr14.3%19.0%0.7x
2023-0166.2x₹8508 cr14.3%19.0%0.7x
2022-1267.5x₹8508 cr14.3%19.0%0.7x
2022-1172.3x₹8508 cr14.3%19.0%0.7x
2022-1071.8x₹8508 cr14.3%19.0%0.7x
2022-0967.9x₹8508 cr14.3%19.0%0.7x
2022-0867.5x₹8508 cr14.3%19.0%0.7x
2022-0766.6x₹8508 cr14.3%19.0%0.7x
2022-0662.3x₹8508 cr14.3%19.0%0.7x
2022-0538.3x₹8005 cr23.4%17.0%0.8x
2022-0438.0x₹8005 cr23.4%17.0%0.8x
2022-0337.7x₹8005 cr23.4%17.0%0.8x
2022-0237.2x₹8005 cr23.4%17.0%0.8x
2022-0136.1x₹8005 cr23.4%17.0%0.8x
2021-1244.3x₹8005 cr23.4%17.0%0.8x
2021-1141.1x₹8005 cr23.4%17.0%0.8x
2021-1038.7x₹8005 cr23.4%17.0%0.8x
2021-0941.7x₹8005 cr23.4%17.0%0.8x
2021-0842.0x₹8005 cr23.4%17.0%0.8x
2021-0741.5x₹8005 cr23.4%17.0%0.8x
2021-0639.2x₹8005 cr23.4%17.0%0.8x
2021-0545.3x₹7939 cr23.2%15.0%1.2x
2021-0441.4x₹7939 cr23.2%15.0%1.2x
2021-0342.0x₹7939 cr23.2%15.0%1.2x
2021-0240.1x₹7939 cr23.2%15.0%1.2x
2021-0143.1x₹7939 cr23.2%15.0%1.2x
2020-1246.3x₹7939 cr23.2%15.0%1.2x
2020-1143.2x₹7939 cr23.2%15.0%1.2x
2020-1042.4x₹7939 cr23.2%15.0%1.2x
2020-0946.2x₹7939 cr23.2%15.0%1.2x
2020-0843.9x₹7939 cr23.2%15.0%1.2x
2020-0744.0x₹7939 cr23.2%15.0%1.2x
2020-0639.2x₹7939 cr23.2%15.0%1.2x
2020-0591.6x₹7673 cr10.1%13.0%1.3x
2020-0491.0x₹7673 cr10.1%13.0%1.3x
2020-0376.5x₹7673 cr10.1%13.0%1.3x
2020-0283.4x₹7673 cr10.1%13.0%1.3x
2020-0174.9x₹7673 cr10.1%13.0%1.3x
2019-1271.7x₹7673 cr10.1%13.0%1.3x
2019-1173.6x₹7673 cr10.1%13.0%1.3x
2019-1068.9x₹7673 cr10.1%13.0%1.3x
2019-0964.7x₹7673 cr10.1%13.0%1.3x
2019-0866.2x₹7673 cr10.1%13.0%1.3x
2019-0764.8x₹7673 cr10.1%13.0%1.3x
2019-0660.0x₹7673 cr10.1%13.0%1.3x
2019-0539.0x₹5950 cr16.0%13.0%1.4x
2019-0444.7x₹5950 cr16.0%13.0%1.4x
2019-0348.6x₹5950 cr16.0%13.0%1.4x
2019-0245.0x₹5950 cr16.0%13.0%1.4x
2019-0145.4x₹5950 cr16.0%13.0%1.4x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback